Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CBYL719F12401
Novartis Pharmaceuticals
PIK3CA-Related Overgrowth Spectrum (PROS)
1 trial -
CBYL719X2402
Novartis Pharmaceuticals
Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer
1 trial -
CCFZ533H12201BC
Novartis Pharmaceuticals
Moderate to severe hidradenitis suppurativa
1 trial -
CDFV890B12201
Novartis Pharmaceuticals
Knee Osteoarthritis
1 trial -
CDZR123A02101
Novartis Pharmaceuticals
advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))
1 trial -
CDZR123A12107
Novartis Pharmaceuticals
Metastatic castrate resistant prostate cancer (mCRPC)
1 trial -
CDZR123C12101
Novartis Pharmaceuticals
Metastatic hormone-sensitive prostate cancer
1 trial -
CECI830A12101
Novartis Pharmaceuticals
Advanced solid tumors, Advanced HR+/HER2- breast cancer
1 trial -
CFWY003A12201
Novartis Pharmaceuticals
Geographic atrophy secondary to age-related macular degeneration
1 trial -
CGIA632A12201
Novartis Pharmaceuticals
Atopic dermatitis
1 trial -
CGVV858A12101
Novartis Pharmaceuticals
Advanced HR+/HER- breast cancer
1 trial -
CGXV813B12201
Novartis Pharmaceuticals
Schizophrenia
1 trial -
CINC280A2X02B
Novartis Pharmaceuticals
cMET-dependent malignancies
1 trial -
CJDQ443A12101
Novartis Pharmaceuticals
Advance solid tumors harboring the KRAS G12C mutation
1 trial -
CJDQ443E12101
Novartis Pharmaceuticals
Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
1 trial -
CJSB462B12201
Novartis Pharmaceuticals
Metastatic castration resistant prostate cancer (mCRPC)
1 trial -
CJSB462C12201
Novartis Pharmaceuticals
Metastatic hormone-sensitive prostate cancer
1 trial -
CLEE011Q12101
Novartis Pharmaceuticals
Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)
1 trial -
CLEE011X2107
Novartis Pharmaceuticals
Advanced HR+ breast cancer
1 trial -
CLEE011X2X01B
Novartis Pharmaceuticals
Different types of advanced cancer
1 trial -
CLNP023K12201
Novartis Pharmaceuticals
Lupus Nephritis Class III-IV, +/- V
1 trial -
CLNP023R12201
Novartis Pharmaceuticals
active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis
1 trial -
CLOU064M12101
Novartis Pharmaceuticals
Chronic Inducible urticaria and Chronic Spontaneous Urticaria
1 trial -
CLTP001A12202
Novartis Pharmaceuticals
Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.